AERI Aerie Pharmaceuticals Inc.

29.53
-0.67  -2%
Previous Close 30.2
Open 30.23
Price To Book 7.07
Market Cap 1,355,953,638
Shares 45,917,834
Volume 545,613
Short Ratio
Av. Daily Volume 576,879

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced March 12, 2019.
Roclatan
Glaucoma
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
Rhopressa
Glaucoma
Phase 1/2 trial to be initiated 2Q 2019.
AR-13503
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Phase 2 trial initiated March 2019.
AR-1105
Macular edema due to RVO (retinal vein occlusion)